



# Pharmaids Pharmaceuticals Limited

Date: 11.11.2023

To  
The Manager  
Corporate Relations Department  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street  
Mumbai – 400001

Dear Sir/Madam,

**Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018**

**Sub: Submission of Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for the quarter and Half year ended 30<sup>th</sup> September, 2023.**

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Unaudited Standalone and Consolidated Financial Results along with Limited Review Report issued by M/s PPKG & Co., Statutory Auditors of the Company, for the quarter and half year ended 30<sup>th</sup> September, 2023.

The Financial Results are also available on the website of the company at [www.pharmaids.com](http://www.pharmaids.com) and on the website of BSE [www.bseindia.com](http://www.bseindia.com)

The Board Meeting commenced at 4:00 P.M. and concluded at 05:06 P.M.

Kindly take the same on your record and oblige.

Thanking You

**For Pharmaids Pharmaceuticals Limited**

**Kaushik Kumar**  
**(Company Secretary & Head-Legal)**

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED  
STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND  
HALF YEAR ENDED ON 30<sup>TH</sup> SEPTEMBER, 2023.**

To  
The Board of Directors,  
Pharmaids Pharmaceuticals Limited.

We have reviewed the accompanying statement of unaudited Financial Results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the quarter and half year ended 30th September, 2023 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. CIRJCFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For PPKG & Co.**

Chartered Accountants

FRN No. 009655S



**Girdhari Lal Toshniwal**

(Partner)

M. No.: 205140

UDIN: 23205140BGUNQB6950

**Place:** Hyderabad

**Date:** 11/11/2023





# Pharmaids Pharmaceuticals Limited

## STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(₹ In Lakhs, except Earnings per share data)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		(Un-Audited)	(Un-Audited)	((Un-Audited))	(Un-Audited)	(Un-Audited)	(Audited)
		Sep 30, 2023	June 30, 2023	Sep 30, 2022	Sep 30, 2023	Sep 30, 2022	March 31, 2023
	<b>Income</b>	-	-	-	-	-	-
1	Revenue	-	-	-	-	-	-
2	Other Income	(25.77)	37.21	-	11.43	-	-
3	<b>Total Income</b>	<b>(25.77)</b>	<b>37.21</b>	<b>-</b>	<b>11.43</b>	<b>-</b>	<b>-</b>
4	<b>Expenses</b>	-	-	-	-	-	-
	a) Cost of Material Consumed	-	-	-	-	-	88.76
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	-	-	-	-
	d) Employee Benefit Expenses	47.22	36.14	31.56	83.35	33.64	113.10
	e) Finance Cost	0.01	0.12	0.02	0.13	0.28	0.33
	f) Depreciation and Amortisation Expenses	0.87	0.82	0.63	1.69	0.71	1.68
	g) Other Expenses	54.86	124.63	21.97	179.49	25.35	786.89
	<b>Total Expenses</b>	<b>102.96</b>	<b>161.71</b>	<b>54.18</b>	<b>264.66</b>	<b>59.98</b>	<b>990.76</b>
5	<b>Profit/(loss) before Exceptional items and Tax</b>	<b>(128.73)</b>	<b>(124.50)</b>	<b>(54.18)</b>	<b>(253.23)</b>	<b>(59.98)</b>	<b>(990.76)</b>
6	Exceptional Items	-	-	-	-	-	-
	Prior period share of profit/interest from Associate firm	-	3.81	-	3.81	-	-
7	<b>Profit/(loss) before tax</b>	<b>(128.73)</b>	<b>(120.68)</b>	<b>(54.18)</b>	<b>(249.42)</b>	<b>(59.98)</b>	<b>(990.76)</b>
8	Tax expense:						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	(78.29)	9.35	0.36	(68.94)	8.84	(235.20)
9	<b>Profit (Loss) for the period from continuing operations</b>	<b>(50.44)</b>	<b>(130.03)</b>	<b>(54.54)</b>	<b>(180.48)</b>	<b>(68.82)</b>	<b>(755.57)</b>
10	<b>Profit/(loss) from discontinued operations</b>	-	-	-	-	-	-
11	Tax expense of discontinued operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinued operations (After tax)	-	-	-	-	-	-
13	<b>Profit/(loss) for the period</b>	<b>(50.44)</b>	<b>(130.03)</b>	<b>(54.54)</b>	<b>(180.48)</b>	<b>(68.82)</b>	<b>(755.57)</b>
14	<b>Other Comprehensive Income</b>						
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-





# Pharmaids Pharmaceuticals Limited

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		(Un-Audited)	(Un-Audited)	((Un-Audited))	(Un-Audited)	(Un-Audited)	(Audited)
		Sep 30, 2023	June 30, 2023	Sep 30, 2022	Sep 30, 2023	Sep 30, 2022	March 31, 2023
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15	<b>Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	(50.44)	(130.03)	(54.54)	(180.48)	(68.82)	(755.57)
16	<b>Paid-up Equity share capital (Face value Rs. 10/- per share)</b>	2,144.38	2,144.38	1,026.88	2,144.38	1,026.88	2,144.38
17	<b>Other Equity (excluding revaluation reserve)</b>						63.46
18	<b>Earnings Per Share (of Rs. 10/- each) (not annualised)</b>						
	<b>(1) Basic</b>	(0.24)	(0.61)	-	(0.84)	-	(5.86)
	<b>(2) Diluted</b>	(0.23)	(0.58)	-	(0.81)	-	(5.86)

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

Date: 11.11.2023  
Place: Bangalore

Venu Madhava Kaparthy  
Director  
DIN: 00021699



# Pharmaids Pharmaceuticals Limited

## **NOTES:**

1. The above results were reviewed and recommended by the Audit committee and approved by the Board of Directors at its meeting held on Saturday, 11<sup>th</sup> November 2023.
2. The financial results have been prepared in accordance with applicable accounting standards prescribed under section 133 of Companies Act, 2013 read with (Indian Accounting Standard) Rules, 2015 (Ind AS), as amended from time to time, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).
3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review Report by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation.
4. The Company operates in a single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
5. Previous period figures have been reclassified and regrouped wherever considered necessary to conform to the current period figures.



# Pharmaids Pharmaceuticals Limited

## UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023

(Rupees in lakhs)

	Particulars	As at 30.09.2023	As at 31.03.2023
1	<b>ASSETS</b>		
	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	1,066.50	10.61
	(b) Capital work-in-progress	213.74	200.00
	(c) Investment Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological Assets other than bearer plants	-	-
	(h) Financial Assets	-	-
	(i) Investments	351.46	-
	(ii) Trade receivables	-	66.89
	(iii) Loans	-	147.16
	(iv) Others (to be specified)	-	-
	(i) Deferred tax assets (net)	339.69	270.75
	(j) Other non-current assets	8.50	12.06
	<b>Total Non-Current Assets</b>	<b>1,979.90</b>	<b>707.48</b>
2	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial Assets	-	-
	(i) Investments	-	327.04
	(ii) Trade receivables	-	138.53
	(iii) Cash and cash equivalents	93.05	1,275.42
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans and Advances	13.40	-
	(vi) Others (to be specified)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other current assets	-	6.79
	<b>Total Current Assets</b>	<b>106.45</b>	<b>1,747.78</b>
	<b>Total Assets</b>	<b>2,086.35</b>	<b>2,455.25</b>
	<b>EQUITY AND LIABILITIES Equity</b>		
	(a) Equity Share capital	2,144.38	2,144.38
	(b) Other Equity	(82.33)	98.15
	<b>Total Equity</b>	<b>2,062.05</b>	<b>2,242.53</b>
	<b>LIABILITIES</b>		
1	<b>Non-current liabilities</b>		





# Pharmaids Pharmaceuticals Limited

	Particulars	As at 30.09.2023	As at 31.03.2023
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (Net)	-	-
	(d) Other non-current liabilities	-	-
	<b>Total Non-Current Liabilities</b>	<b>-</b>	<b>-</b>
2	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	14.16	188.31
	(iii) Other financial liabilities (other than those specified in item (c))	-	-
	(b) Other current liabilities	10.14	24.42
	(c) Provisions	-	-
	(d) Current Tax Liabilities (Net)	-	-
	<b>Total Current Liabilities</b>	<b>24.30</b>	<b>212.72</b>
	<b>Total Equity and Liabilities</b>	<b>2,086.35</b>	<b>2,455.25</b>

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy  
Director  
DIN:00021699  
Date: 11.11.2023  
Place: Bangalore



# Pharmaids Pharmaceuticals Limited

## STATEMENT OF UNAUDITED STANDALONE CASH FLOW FOR THE HALF YEAR ENDED ON SEPTEMBER 30, 2023

(Rupees in lakhs)

	Particulars	Figures as at the end of 30.09.2023 (Unaudited)	Figures as at the end of 30.09.2022 (Unaudited)
<b>A</b>	<b>CASHFLOW FROM OPERATING ACTIVITIES:</b>		
	Net Profit before Tax	(249.42)	(59.98)
	Adjustment for:		
	Depreciation and Amortization	1.69	0.71
	Share of Interest & Profit/Loss from Associate	60.58	-
	Interest Income	(11.08)	-
	Provision / write off for doubtful trade receivables	80.81	-
	Write back of trade payables	(64.74)	-
	<b>Operating Profit before change in working capital</b>	<b>(182.16)</b>	<b>(59.27)</b>
	<b>Working capital changes:</b>		
	Changes in Inventories	-	-
	Changes in Trade Receivables	124.61	143.54
	Change in Short term loans and advances	(13.40)	49.63
	Changes in Trade payables	(109.41)	(226.63)
	Changes in Other liabilities	(14.28)	12.00
	Change in Long Term Loans & Advances	147.16	-
	Changes in Other Non-current assets	3.56	-
	Changes in Other Current Assets	6.79	(5.51)
	<b>Cash generated from Operations</b>	<b>(37.12)</b>	<b>(86.24)</b>
	Direct tax paid (Net of Refunds)	-	-
	<b>Net Cash inflow from Operating Activities (A)</b>	<b>(37.12)</b>	<b>(86.24)</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Interest received	11.08	-
	Investment in Associate	(85.00)	-
	Purchase of property, plant & equipments, intangible assets and Capital Advance	(1,057.58)	(9.35)
	Increase in Capital Work In Progress	(13.74)	-
	<b>Net Cash inflow from Investing Activities (B)</b>	<b>(1,145.25)</b>	<b>(9.35)</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Proceeds from borrowings	-	100.00
	<b>Net Cash inflow from Financing Activities (C)</b>	<b>-</b>	<b>100.00</b>
<b>I</b>	<b>Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>(1,182.37)</b>	<b>4.41</b>
<b>II</b>	<b>a) Cash and Cash Equivalents at the beginning of the year</b>	<b>1,275.42</b>	<b>40.74</b>



# Pharmaids Pharmaceuticals Limited

	Particulars	Figures as at the end of 30.09.2023 (Unaudited)	Figures as at the end of 30.09.2022 (Unaudited)
	b) Effect of Exchange difference on restatement of foreign currency cash and cash equivalents	-	-
	c) Effect of Fairvalue change of investment held for Trading	-	-
III	Cash and Cash Equivalents at the end of the year/period (I+II)	93.05	45.15
	Balances with Banks	91.99	37.60
	Cash on Hand	1.06	7.55
	Total Cash and Cash Equivalents	93.05	45.15

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy  
Director  
DIN:00021699  
Date: 11.11.2023  
Place: Bangalore



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND HALF YEAR ENDED ON 30<sup>TH</sup> SEPTEMBER, 2023.**

To The Board of Directors,

**Pharmaids Pharmaceuticals Limited.,**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Pharmaids Pharmaceuticals Limited.** ("the Company") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter and half year ended September 30, 2023, and for the period from April 01, 2023 to September 30, 2023 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter ended September 30, 2023 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and In compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of **Anugraha Chemicals. (Associate Company)**
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 474.57 lakhs, total net Loss after tax of Rs. 173.80 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter ended September 30, 2023 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of these Associates, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

**For PPKG & Co**

Chartered Accountants

FRN No. 009655S



**Girdhari Lal Toshniwal**

(Partner)

M.No. 205140

UDIN: 23205740BGUNOC 7801

**Place:** Hyderabad

**Date:** 11/11/2023



# Pharmaids Pharmaceuticals Limited

## STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(₹ In Lakhs, except Earnings per share data)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		(Un-Audited)	(Un-Audited)	((Un-Audited))	(Un-Audited)	(Un-Audited)	(Audited)
		Sep 30, 2023	June 30, 2023	Sep 30, 2022	Sep 30, 2023	Sep 30, 2022	March 31, 2023
	<b>Income</b>						
1	Revenue	-	-	-	-	-	-
2	Other Income	(25.77)	37.21	-	11.43	-	-
3	<b>Total Income</b>	<b>(25.77)</b>	<b>37.21</b>	<b>-</b>	<b>11.43</b>	<b>-</b>	<b>-</b>
4	<b>Expenses</b>						
	a) Cost of Material Consumed	-	-	-	-	-	88.76
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	-	-	-	-
	d) Employee Benefit Expenses	47.22	36.14	31.56	83.35	33.64	113.10
	e) Finance Cost	0.01	0.12	0.02	0.13	0.28	0.33
	f) Depreciation and Amortisation Expenses	0.87	0.82	0.63	1.69	0.71	1.68
	g) Other Expenses	54.86	124.63	21.97	179.49	25.35	786.89
	<b>Total Expenses</b>	<b>102.96</b>	<b>161.71</b>	<b>54.18</b>	<b>264.66</b>	<b>59.98</b>	<b>990.76</b>
5	<b>Profit/(loss) before Exceptional items and Tax</b>	<b>(128.73)</b>	<b>(124.50)</b>	<b>(54.18)</b>	<b>(253.23)</b>	<b>(59.98)</b>	<b>(990.76)</b>
6	Exceptional Items	-	-	-	-	-	-
	Prior period share of profit/interest from Associate firm	-	3.81		3.81		-
7	<b>Profit/(loss) before tax</b>	<b>(128.73)</b>	<b>(120.68)</b>	<b>(54.18)</b>	<b>(249.42)</b>	<b>(59.98)</b>	<b>(990.76)</b>
8	Tax expense:						
	(1) Current tax						
	(2) Deferred tax	(78.29)	9.35	0.36	(68.94)	8.84	(235.20)
9	<b>Profit (Loss) for the period from continuing operations</b>	<b>(50.44)</b>	<b>(130.03)</b>	<b>(54.54)</b>	<b>(180.48)</b>	<b>(68.82)</b>	<b>(755.57)</b>
10	<b>Profit/(loss) from discontinued operations</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
11	Tax expense of discontinued operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinued operations (After tax)	-	-	-	-	-	-
13	<b>Profit/(loss) for the period</b>	<b>(50.44)</b>	<b>(130.03)</b>	<b>(54.54)</b>	<b>(180.48)</b>	<b>(68.82)</b>	<b>(755.57)</b>
14	<b>Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3.48</b>





# Pharmaids Pharmaceuticals Limited

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		(Un-Audited)	(Un-Audited)	((Un-Audited))	(Un-Audited)	(Un-Audited)	(Audited)
		Sep 30, 2023	June 30, 2023	Sep 30, 2022	Sep 30, 2023	Sep 30, 2022	March 31, 2023
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15	<b>Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>(50.44)</b>	<b>(130.03)</b>	<b>(54.54)</b>	<b>(180.48)</b>	<b>(68.82)</b>	<b>(752.09)</b>
16	<b>Paid-up Equity share capital (Face value Rs. 10/- per share)</b>	<b>2,144.38</b>	<b>2,144.38</b>	<b>1,026.88</b>	<b>2,144.38</b>	<b>1,026.88</b>	<b>2,144.38</b>
17	<b>Other Equity (excluding revaluation reserve)</b>						<b>66.94</b>
16	<b>Earnings Per Share (of Rs. 10/- each) (not annualised):</b>						
	<b>(1) Basic</b>	<b>(0.24)</b>	<b>(0.61)</b>	<b>-</b>	<b>(0.84)</b>	<b>-</b>	<b>(5.86)</b>
	<b>(2) Diluted</b>	<b>(0.23)</b>	<b>(0.58)</b>	<b>-</b>	<b>(0.81)</b>	<b>-</b>	<b>(5.86)</b>

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy  
Director  
DIN:00021699  
Date: 11.11.2023  
Place: Bangalore



# Pharmaids Pharmaceuticals Limited

## **NOTES:**

1. The above results were reviewed and recommended by the Audit committee and approved by the Board of Directors at its meeting held on Saturday, 11<sup>th</sup> November 2023.
2. The financial results have been prepared in accordance with applicable accounting standards prescribed under section 133 of Companies Act, 2013 read with (Indian Accounting Standard) Rules, 2015 (Ind AS), as amended from time to time, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).
3. Company holds 37.16% partnership interest in Anugraha Chemicals (“Firm”), a Partnership Firm, registered under Karnataka Partnership (Registration of Firms) Rules, 1954. The Financials of the Firm has been consolidated as per the applicable Ind AS.
4. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review Report by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation.
5. The Company operates in a single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
6. Previous period figures have been reclassified and regrouped wherever considered necessary to conform to the current period figures.



# Pharmaids Pharmaceuticals Limited

## UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2023

(Rupees in lakhs)

	Particulars	As at 30.09.2023	As at 31.03.2023
1	<b>ASSETS</b>		
	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	1,066.50	10.61
	(b) Capital work-in-progress	213.74	200.00
	(c) Investment Property	-	-
	(d) Goodwill	-	-
	(e) Other Intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological Assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	351.46	-
	(ii) Trade receivables	-	66.89
	(iii) Loans	-	147.16
	(iv) Others (to be specified)	-	-
	(i) Deferred tax assets (net)	339.69	270.75
	(j) Other non-current assets	8.50	12.06
	<b>Total Non-Current Assets</b>	<b>1,979.90</b>	<b>707.48</b>
2	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	330.52
	(ii) Trade receivables	-	138.53
	(iii) Cash and cash equivalents	93.05	1,275.42
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans and Advances	13.40	-
	(vi) Others (to be specified)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other current assets		6.79
	<b>Total Current Assets</b>	<b>106.45</b>	<b>1,751.26</b>
	<b>Total Assets</b>	<b>2,086.35</b>	<b>2,458.73</b>
	<b>EQUITY AND LIABILITIES Equity</b>		
	(a) Equity Share capital	2,144.38	2,144.38
	(b) Other Equity	(82.33)	101.63
	<b>Total Equity</b>	<b>2,062.05</b>	<b>2,246.01</b>
	<b>LIABILITIES</b>		





# Pharmaids Pharmaceuticals Limited

	Particulars	As at 30.09.2023	As at 31.03.2023
1	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions		
	(c) Deferred tax liabilities (Net)		
	(d) Other non-current liabilities		
	<b>Total Non-Current Liabilities</b>	-	-
2	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings		
	(ii) Trade payables	14.16	188.31
	(iii) Other financial liabilities (other than those specified in item (c))		
	(b) Other current liabilities	10.14	24.42
	(c) Provisions		
	(d) Current Tax Liabilities (Net)		
	<b>Total Current Liabilities</b>	<b>24.30</b>	<b>212.72</b>
	<b>Total Equity and Liabilities</b>	<b>2,086.35</b>	<b>2,458.73</b>

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy  
Director  
DIN:00021699  
Date: 11.11.2023  
Place: Bangalore



# Pharmaids Pharmaceuticals Limited

## STATEMENT OF UNAUDITED STANDALONE CASH FLOW FOR THE HALF YEAR ENDED ON SEPTEMBER 30, 2023

(Rupees in lakhs)

	Particulars	Figures as at the end of 30.09.2023 (Unaudited)	Figures as at the end of 30.09.2022 (Unaudited)
<b>A</b>	<b>CASHFLOW FROM OPERATING ACTIVITIES:</b>		
	Net Profit before Tax	(249.42)	(59.98)
	Adjustment for:		
	Depreciation and Amortization	1.69	0.71
	Share of Interest & Profit/Loss from Associate	60.58	-
	Interest Income	(11.08)	-
	Provision / write off for doubtful trade receivables	80.81	-
	Write back of trade payables	(64.74)	-
	Operating Profit before change in working capital	(182.16)	(59.27)
	Working capital changes:		
	Changes in Inventories	-	-
	Changes in Trade Receivables	124.61	143.54
	Change in Short term loans and advances	(13.40)	49.63
	Changes in Trade payables	(109.41)	(226.63)
	Changes in Other liabilities	(14.28)	12.00
	Change in Long Term Loans & Advances	147.16	-
	Changes in Other Non-current assets	3.56	-
	Changes in Other Current Assets	6.79	(5.51)
	Cash generated from Operations	(37.12)	(86.24)
	Direct tax paid (Net of Refunds)		
	Net Cash inflow from Operating Activities (A)	(37.12)	(86.24)
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Interest received	11.08	-
	Investment in Associate	(85.00)	-
	Purchase of property, plant & equipments, intangible assets and Capital Advance	(1,057.58)	(9.35)
	Increase in Capital Work In Progress	(13.74)	
	Net Cash inflow from Investing Activities (B)	(1,145.25)	(9.35)
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Proceeds from borrowings	-	100.00
	Net Cash inflow from Financing Activities (C)	-	100.00
<b>I</b>	<b>Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>(1,182.37)</b>	<b>4.41</b>
<b>II</b>	<b>a) Cash and Cash Equivalents at the beginning of the year</b>	<b>1,275.42</b>	<b>40.74</b>



# Pharmaids Pharmaceuticals Limited

	Particulars	Figures as at the end of 30.09.2023 (Unaudited)	Figures as at the end of 30.09.2022 (Unaudited)
	b) Effect of Exchange difference on restatement of foreign currency cash and cash equivalents	-	-
	c) Effect of Fairvalue change of investment held for Trading	-	-
<b>III</b>	<b>Cash and Cash Equivalents at the end of the year/period (I+II)</b>	<b>93.05</b>	<b>45.15</b>
	Balances with Banks	91.99	37.60
	Cash on Hand	1.06	7.55
	Total Cash and Cash Equivalents	93.05	45.15

By the order of the Board of Directors  
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy  
Director  
DIN:00021699  
Date: 11.11.2023  
Place: Bangalore